Cardiovascular Metabolomics.
Cardiovascular Metabolomics.
复制标题
DOI：
10.1161/circresaha.117.311002
复制
发表时间：
2018-04-27
影响因子：
20.1
通讯作者：
Newgard CB
中科院分区：
文献类型：
--
作者：
McGarrah RW;Crown SB;Zhang GF;Shah SH;Newgard CB
心脏代谢紊乱是大多数心血管疾病的基础。代谢组学是较新的“组学”技术之一，已成为一种强有力的工具，用于定义发生在一系列心血管疾病状态中的全局和心脏特异性代谢的变化。代谢组学研究的结果有助于更好地理解心力衰竭和缺血性心脏病中发生的代谢变化，并确定了新的心血管疾病生物标志物。随着技术的进步，代谢组学领域继续迅速发展。在这篇综述中，我们将讨论代谢组学技术的现状，包括考虑各种代谢组学平台和研究设计的要素;稳定同位素在代谢通量研究中的新兴效用;以及使用代谢组学更好地了解特定的心血管疾病，重点是该领域的最新进展。
Disturbances in cardiac metabolism underlie most cardiovascular diseases. Metabolomics, one of the newer “omics” technologies, has emerged as a powerful tool for defining changes in both global and cardiac-specific metabolism that occur across a spectrum of cardiovascular disease states. Findings from metabolomics studies have contributed to better understanding of the metabolic changes that occur in heart failure and ischemic heart disease and have identified new cardiovascular disease biomarkers. As technologies advance, the metabolomics field continues to evolve rapidly. In this review, we will discuss the current state of metabolomics technologies, including consideration of various metabolomics platforms and elements of study design; the emerging utility of stable isotopes for metabolic flux studies; and the use of metabolomics to better understand specific cardiovascular diseases, with an emphasis on recent advances in the field.